Antivascular endothelial growth factor-a treatment: new perspectives for high-risk plaque stabilization.
Toutouzas
Konstantinos
K
Karabelas
John
J
Vaina
Sophia
S
Stefanadis
Christodoulos
C
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003324:Coronary Artery Disease / Q000188:drug therapy*; D006801:Humans; D042461:Vascular Endothelial Growth Factor A / Q000009:adverse effects / Q000276:immunology*; D042442:Vascular Endothelial Growth Factors / Q000627:therapeutic use*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D000068258:Bevacizumab